Recipient Information

2025

2022

GENENTECH INC

1, DNA WAY

SOUTH SAN FRANCISCO

CA

94080-4990

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

000

3

FDA

1/30/2025

-$217,353

2023

2021

GENENTECH INC

1, DNA WAY

SOUTH SAN FRANCISCO

CA

94080-4990

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

000

2

FDA

6/29/2023

$0

2022

GENENTECH INC

1, DNA WAY

SOUTH SAN FRANCISCO

CA

94080

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

001

3

FDA

8/31/2022

$232,798

2022

GENENTECH INC

1, DNA WAY

SOUTH SAN FRANCISCO

CA

94080

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

001

3

FDA

8/31/2022

$27,959

2022

2021

GENENTECH, INC.

1 DNA WAY

SOUTH SAN FRANCISCO

CA

94080-4990

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

000

2

FDA

6/7/2022

$0

2021

GENENTECH, INC.

1 DNA WAY

SOUTH SAN FRANCISCO

CA

94080-4990

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

000

2

FDA

7/9/2021

$256,284

2020

GENENTECH, INC.

1 DNA WAY

SOUTH SAN FRANCISCO

CA

94080-4990

SAN MATEO

USA

U01FD007206

Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source

000

1

FDA

8/31/2020

$251,057

1998

GENENTECH, INC

1 DNA WAY

SO SAN FRANCISCO

CA

94080

USA

F32GM019454

BIOLOGICALLY RELEVANT ALPHA HELIX STABILIZATION

000

1

NIH

12/21/1998

$0

1997

GENENTECH, INC

1 DNA WAY

SO SAN FRANCISCO

CA

94080

USA

F32DK09755

PHAGE VS COMBINATORIAL LIBRARY OF BIOTIN ANALOGS

000

01

NIH

9/30/1997

$24,292

1996

GENENTECH, INC

1 DNA WAY

SO SAN FRANCISCO

CA

94080

USA

F32GM16549

SEMISYNTHETIC ENGINEERING OF HUMAN GROWTH HORMONE

000

03

NIH

11/30/1995

$27,600

1995

GENENTECH, INC

1 DNA WAY

SO SAN FRANCISCO

CA

94080

USA

F32GM16549

SEMISYNTHETIC ENGINEERING OF HUMAN GROWTH HORMONE

000

02

NIH

12/10/1994

$22,700

All Categories

About

Search

Reports

Data Submission

Recipient Information

GENENTECH INC

Address: 1, DNA WAY SOUTH SAN FRANCISCO, CA 94080-4990

County: SAN MATEO

Country: UNITED STATES

UEI: F7F8GZXL7Q93

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer